Target technologies set the standard for protein biomarker research and identification. Using Olink's Proximity Extension Assay (PEA) technology, Target 48 and 96 offer flexible, high-throughput options for researchers interested in immuno-oncology, neurology, cardiology, and many other specialties. This technology has opened the door to countless insights on biological processes.
Psomagen has also added a gold service badge for Olink® Flex after undergoing a similar certification process. Flex is a highly customizable option for researchers interested in investigating specific protein biomarkers, particularly in inflammation studies. Users can select up to 21 human proteins from a list of over 200, then combine them in one biomarker panel.
"This is a phenomenal opportunity for our labs and Psomagen clients," says Dr. Su Hong, Psomagen's CEO. "Receiving this extra training allows us to provide high quality results on very versatile platforms. This is a huge step forward for inflammation and disease research endeavors."
Psomagen has been a provider of Olink® platforms since late 2021. We were the first North American company to receive a platinum badge for Olink® Explore, a tool to build protein profiles focused on oncologic, neurologic, inflammatory, and cardiometabolic disease. We also offer Olink® Focus, which allows researchers to investigate up to 21 proteins not covered by other panels.
About Psomagen
Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
Contact
Harold Nuñez
Business Development
harold@psomagen.com
301-251-1007 x531
About Olink
Olink Proteomics AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink Proteomics provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st-century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America, and Asia. Olink Proteomics is headquartered in Uppsala, Sweden.